YY-20394

DRUG9 trials

Sponsors

Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions

Advanced Solid TumorB-cell Chronic Lymphocytic LeukemiaB-cell Lymphoma RecurrentDiffuse Large B Cell LymphomaEffectiveness，Safety，Thymic CancerFollicular LymphomaLymphoma, FollicularLymphoplasmacytic Lymphoma

Phase 1

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

Shanghai YingLi Pharmaceutical Co. Ltd.B-cell Chronic Lymphocytic Leukemia, B-cell Lymphoma Recurrent

Start: 2017-12-25End: 2019-05-30Target: 42Updated: 2018-12-10

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Shanghai YingLi Pharmaceutical Co. Ltd.Advanced Solid Tumor

Start: 2019-08-31End: 2020-10-31Target: 50Updated: 2019-08-08

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Shanghai YingLi Pharmaceutical Co. Ltd.Relapsed or Refractory Peripheral T-Cell Lymphoma

Start: 2020-03-30End: 2021-12-31Target: 58Updated: 2021-01-28

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

CompletedNCT04279405

Shanghai YingLi Pharmaceutical Co. Ltd.Diffuse Large B Cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma +2

Start: 2020-06-15End: 2023-06-01Updated: 2024-06-13

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Shanghai YingLi Pharmaceutical Co. Ltd.Diffuse Large B Cell Lymphoma

Start: 2020-08-20End: 2021-12-01Target: 28Updated: 2020-08-05

Phase 2

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Shanghai YingLi Pharmaceutical Co. Ltd.Lymphoma, Follicular

Start: 2019-04-29End: 2021-02-22Target: 123Updated: 2020-05-11

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Shanghai YingLi Pharmaceutical Co. Ltd.Follicular Lymphoma

Start: 2020-12-30End: 2022-12-30Target: 140Updated: 2020-05-07

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Shanghai YingLi Pharmaceutical Co. Ltd.Peripheral T/NK Cell Lymphoma (R/R PTCL)

Start: 2022-05-01End: 2023-12-01Target: 97Updated: 2022-10-21

Unknown Phase

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

Shanghai YingLi Pharmaceutical Co. Ltd.Effectiveness，Safety，Thymic Cancer

Start: 2021-08-01End: 2022-12-30Target: 58Updated: 2021-07-23

Related Papers

Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.

2026-03-10

Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

2025-11-25

Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

2025-11-25

Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib.

Blood2025-11-03

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial

Cancer Cell International2025-02-08

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Blood2024-11-051 citations

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Blood2024-11-05

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood2023-11-02

Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study

Blood2023-11-02

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Blood2023-11-02

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

HemaSphere2023-08-01

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

HemaSphere2023-08-01

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY

HemaSphere2023-08-01

CLINICAL OUTCOMES BY PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH LINPERLISIB

Hematological Oncology2023-06-01

A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Blood2022-11-158 citations

A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Blood2021-11-055 citations

Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Blood2021-11-052 citations

A Phase1b Clinical Study of the Oral PI3Kδ Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

Blood2021-11-05

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.

2021-08-2320 citations

A PHASE I<sub>B</sub> STUDY OF AN ORAL PI3Kδ INHIBITOR LINPERLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA

Hematological Oncology2021-06-011 citations

3 more papers not shown